{"_id": "5386343d38f0d83ab0490313", "print_page": null, "blog": [], "byline": {"person": [{"lastname": "GOLDFARB", "rank": 1, "role": "reported", "firstname": "Jeffrey", "organization": ""}], "original": "By JEFFREY GOLDFARB"}, "multimedia": [{"url": "images/2014/05/29/business/dbpix-valeant/dbpix-valeant-thumbWide.jpg", "width": 190, "type": "image", "legacy": {"widewidth": "190", "wide": "images/2014/05/29/business/dbpix-valeant/dbpix-valeant-thumbWide.jpg", "wideheight": "126"}, "subtype": "wide", "height": 126}, {"url": "images/2014/05/29/business/dbpix-valeant/dbpix-valeant-articleLarge.jpg", "width": 600, "type": "image", "legacy": {"xlargeheight": "444", "xlarge": "images/2014/05/29/business/dbpix-valeant/dbpix-valeant-articleLarge.jpg", "xlargewidth": "600"}, "subtype": "xlarge", "height": 444}, {"url": "images/2014/05/29/business/dbpix-valeant/dbpix-valeant-thumbStandard.jpg", "width": 75, "type": "image", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2014/05/29/business/dbpix-valeant/dbpix-valeant-thumbStandard.jpg", "thumbnailheight": "75"}, "subtype": "thumbnail", "height": 75}], "source": "The New York Times", "type_of_material": "Blog", "news_desk": "Business", "snippet": "In its pursuit of the maker of Botox, Valeant Pharmaceuticals has more work to do to reclaim the role of aggressor, writes Jeffrey Goldfarb of Reuters Breakingviews....", "document_type": "blogpost", "subsection_name": "Dealbook", "word_count": "415", "headline": {"kicker": "DealBook", "main": "Valeant's Latest Move Disappoints"}, "lead_paragraph": null, "slideshow_credits": null, "keywords": [{"name": "persons", "rank": "1", "value": "Ackman, William A"}, {"name": "organizations", "rank": "2", "value": "Valeant Pharmaceuticals International Inc"}, {"name": "organizations", "rank": "1", "value": "Allergan Inc"}, {"name": "subject", "rank": "1", "value": "Mergers, Acquisitions and Divestitures"}], "pub_date": "2014-05-28T15:07:20Z", "section_name": "Business Day", "abstract": "In its pursuit of the maker of Botox, Valeant Pharmaceuticals has more work to do to reclaim the role of aggressor, writes Jeffrey Goldfarb of Reuters Breakingviews.", "web_url": "http://dealbook.nytimes.com/2014/05/28/valeants-latest-move-disappoints/"}